MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program

MDM2 is a key negative regulator of the tumor suppressor p53, however, the prognostic significance of MDM2 overexpression in diffuse large B-cell lymphoma (DLBCL) has not been defined convincingly. In a p53 genetically–defined large cohort of de novo DLBCL patients treated with rituximab, cyclophosp...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Xu-Monette, Zijun Y., Møller, Michael B., Tzankov, Alexander, Montes-Moreno, Santiago, Hu, Wenwei, Manyam, Ganiraju C., Kristensen, Louise, Fan, Lei, Visco, Carlo, Dybkær, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Choi, William W. L., van Krieken, J. Han, Huang, Qin, Huh, Jooryung, Ai, Weiyun, Ponzoni, Maurilio, Ferreri, Andrés J. M., Wu, Lin, Zhao, Xiaoying, Bueso-Ramos, Carlos E., Wang, Sa A., Go, Ronald S., Li, Yong, Winter, Jane N., Piris, Miguel A., Medeiros, L. Jeffrey, Young, Ken H.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2013
Teme:
Lymphoid Neoplasia
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3952598/
https://ncbi.nlm.nih.gov/pubmed/23982177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-12-473702
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki